Monte Rosa Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	70.33	123.67	75.62	-	-	-
Revenue Growth	-61.26%	63.54%	-	-	-	-
Cost of Revenue	133.7	133.7	112.86	103.37	-	-
Gross Profit	-63.38	-10.03	-37.24	-103.37	-	-
Selling, General & Admin	49.57	44.18	43.87	39.94	35.12	15.73
Research & Development	37.88	-	-	-	77.26	57.16
Operating Expenses	87.44	44.18	43.87	39.94	112.38	72.88
Operating Income	-150.82	-54.21	-81.11	-143.31	-112.38	-72.88
Interest & Investment Income	20.82	12.94	10.57	9.33	3.76	0.05
Currency Exchange Gain (Loss)	0.06	1.48	0.42	-0.93	0.01	-0.16
Other Non Operating Income (Expenses)	-	-	-	-	-	-0.96
EBT Excluding Unusual Items	-129.94	-39.78	-70.13	-134.91	-108.61	-73.96
Gain (Loss) on Sale of Investments	-	-	-	-0.13	-	-
Gain (Loss) on Sale of Assets	-	0.06	-	0.02	0.11	-
Pretax Income	-129.94	-39.72	-70.13	-135.01	-108.5	-73.96
Income Tax Expense	1.04	-1.1	2.57	0.34	-	-
Net Income	-130.97	-38.63	-72.7	-135.35	-108.5	-73.96
Net Income to Common	-130.97	-38.63	-72.7	-135.35	-108.5	-73.96
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	97	83	74	51	47	25
Shares Outstanding (Diluted)	97	83	74	51	47	25
Shares Change	17.46%	12.39%	43.80%	8.83%	88.91%	1548.09%
EPS (Basic)	-1.35	-0.46	-0.98	-2.63	-2.30	-2.96
EPS (Diluted)	-1.35	-0.46	-0.98	-2.63	-2.30	-2.96
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-174.39	-27.5	38.01	-62.84	-105.38	-69.1
Free Cash Flow Per Share	-1.79	-0.33	0.51	-1.22	-2.23	-2.76
Gross Margin	-90.12%	-8.11%	-49.25%	-	-	-
Operating Margin	-214.46%	-43.83%	-107.26%	-	-	-
Profit Margin	-186.24%	-31.23%	-96.14%	-	-	-
Free Cash Flow Margin	-247.98%	-22.23%	50.26%	-	-	-
EBITDA	-142.64	-45.85	-72.99	-137.09	-108.64	-70.75
EBITDA Margin	-202.83%	-37.08%	-96.52%	-	-	-
D&A For EBITDA	8.18	8.36	8.12	6.22	3.75	2.13
EBIT	-150.82	-54.21	-81.11	-143.31	-112.38	-72.88
EBIT Margin	-214.46%	-43.83%	-107.26%	-	-	-

SEC Filings: 10-K · 10-Q